China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have agreed to collaborate on the overseas business development of Kelun’s high-end generic drugs and innovative therapies. The partnership aims to leverage the strengths of both companies to expand their global footprint.
Agreement Details
Under the terms of the agreement, for which no financial details were disclosed, Kelun Pharma will provide a list of approved and investigational drugs eligible for collaboration, covering multiple therapeutic fields. Kexing Pharma will screen these products and sign separate project cooperation agreements for specific products.
Collaborative Efforts
The two companies will leverage their respective advantages in research and development, manufacturing, and commercialization to jointly promote the regulatory filing, market launch, and sales of these products on a global scale. Their collaboration will not be limited to exclusive commercial rights in overseas markets, localized technology transfer, and cooperative development.
Significance of the Partnership
This strategic partnership between Kexing Pharmaceutical and Kelun Pharmaceutical underscores their commitment to expanding the reach of high-quality generic drugs and innovative therapies worldwide. By combining their expertise, the companies aim to enhance their market presence and provide more accessible treatment options for patients globally.-Fineline Info & Tech
Leave a Reply